Enanta Pharmaceuticals, Inc.ENTANASDAQ
Loading
Operating Expenses Over TimeStable
Percentile Rank53
3Y CAGR-13.5%
5Y CAGR-7.5%
Year-over-Year Change
Expenses from normal business operations (SG&A, R&D, etc.)
3Y CAGR
-13.5%/yr
vs +6.5%/yr prior
5Y CAGR
-7.5%/yr
Recent deceleration
Acceleration
-20.0pp
Decelerating
Percentile
P53
Within normal range
vs 5Y Ago
0.7x
Contraction
Streak
3 yr
Consecutive declineStable
| Period | Value | YoY Change |
|---|---|---|
| TTM | $140.04M | -4.1% |
| 2025 | $146.09M | -22.8% |
| 2024 | $189.33M | -12.5% |
| 2023 | $216.41M | +3.1% |
| 2022 | $210.00M | +1.6% |
| 2021 | $206.65M | +25.9% |
| 2020 | $164.11M | -2.6% |
| 2019 | $168.46M | +42.4% |
| 2018 | $118.30M | +51.3% |
| 2017 | $78.20M | - |